Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users

Journal of Hepatology

Volumn 61, Issue 4, 2014, Pages 738-745

  Sugden, Peter B ^a   Cameron, Barbara ^a   Mina, Michael ^a   Lloyd, Andrew R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

CD4 T cells; CD8 T cells; Exposed uninfected; Genetics; Natural killer cells; Protective immunity

Indexed keywords

CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; HLA C ANTIGEN; INTERLEUKIN 28B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; CD69 ANTIGEN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; KIR2DL3 PROTEIN, HUMAN; LECTIN; LEUKOCYTE ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; T LYMPHOCYTE ANTIGEN;

ADULT; ARTICLE; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG USE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNITY; LIVER PROTECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; T LYMPHOCYTE SUBPOPULATION; COMPLICATION; GENE EXPRESSION PROFILING; GENETICS; HIGH RISK BEHAVIOR; IMMUNOLOGY; PSYCHOLOGY; SUBSTANCE ABUSE;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; DRUG USERS; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS C; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MALE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RECEPTORS, KIR2DL3; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84921366994     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.05.013     Document Type: Article

References (56)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Post J, Ratnarajah S, Lloyd A. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009; 66: 733-756.
3. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99.
4. Bowen DG, Shoukry NH, Grakoui A, Fuller MJ, Cawthon AG, Dong C, et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol 2008; 82: 5109-5114.
5. Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007; 85: 24-32.
6. Al-Sherbiny M, Osman A, Mohamed N, Shata MT, Abdel-Aziz F, Abdel-Hamid M, et al. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg 2005; 73: 44-49.
7. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162: 6681-6689.
8. Bronowicki JP, Vetter D, Uhl G, Hudziak H, Uhrlacher A, Vetter JM, et al. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. J Infect Dis 1997; 176: 518-522.
9. Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78: 12252-12258.
10. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virusspecific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176: 859-866.
11. Della Bella S, Riva A, Tanzi E, Nicola S, Amendola A, Vecchi L, et al. Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born from HCVinfected women. J Hepatol 2005; 43: 394-402.
12. Cameron B, Galbraith S, Li H, Lloyd A. Correlates and characteristics of hepatitis C virus-specific T-cell immunity in exposed uninfected high-risk prison inmates. J Viral Hepat 2013; 20: e96-e106.
13. Freeman AJ, Ffrench RA, Post JJ, Harvey CE, Gilmour SJ, White PA, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190: 1093-1097.
14. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler- Normann C, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008; 198: 203-212.
15. Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008; 198: 1749-1755.
16. Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009; 16: 10-20.
17. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010; 52: 1581-1589.
18. Pelletier S, Drouin C, Bedard N, Khakoo SI, Bruneau J, Shoukry NH. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol 2010; 53: 805-816.
19. Hurtado CW, Golden-Mason L, Brocato M, Krull M, Narkewicz MR, Rosen HR. Innate immune function in placenta and cord blood of hepatitis C- seropositive mother-infant dyads. PLoS One 2010; 5: e12232.
20. Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, et al. Innate immune responses in hepatitis C virus exposed healthcare workers who do not develop acute infection. Hepatology 2013; 58(5): 1621-1631.
21. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-1855.
22. Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, et al. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003; 314: 601-616.
23. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: e118.
24. Zuniga J, Romero V, Azocar J, Terreros D, Vargas-Rojas MI, Torres-Garcia D, et al. Protective KIR-HLA interactions for HCV infection in intravenous drug users. Mol Immunol 2009; 46: 2723-2727.
25. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010; 51: 1168-1175.
26. Dolan K, Teutsch S, Scheuer N, Levy M, Rawlinson W, Kaldor J, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol 2010; 25: 143-148.
27. Teutsch S, Luciani F, Scheuer N, McCredie L, Hosseiny P, Rawlinson W, et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health 2010; 10: 633.
28. Howell J, Sawhney R, Testro A, Skinner N, Gow P, Angus P, et al. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation. Liver Transpl 2013; 19: 1099-1107.
29. Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, et al. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat 2011; 18: 549-561.
30. Keoshkerian E, Helbig K, Beard M, Zaunders J, Seddiki N, Kelleher A, et al. A novel assay for detection of hepatitis C virus-specific effector CD4(+) T cells via co-expression of CD25 and CD134. J Immunol Methods 2012; 375: 148-158.
31. Houtchens KA, Nichols RJ, Ladner MB, Boal HE, Sollars C, Geraghty DE, et al. High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles. Immunogenetics 2007; 59: 525-537.
32. Shearer G, Clerici M. Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us? J Infect Dis 2010; 202: S329-S332.
33. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007; 4: 58.
34. Elliott LN, Lloyd AR, Ziegler JB, Ffrench RA. Protective immunity against hepatitis C virus infection. Immunol Cell Biol 2006; 84: 239-249.
35. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
36. Tomescu C, Abdulhaqq S, Montaner LJ. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp Immunol 2011; 164: 158-169.
37. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012; 481: 394-398.
38. Pembroke T, Rees I, Gallagher K, Jones E, Mizen P, Navruzov T, et al. Rapid early innate control of hepatitis C virus during IFN-a treatment compromises adaptive CD4+T-cell immunity. Eur J Immunol 2012; 42: 2383-2394.
39. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killercell subsets. Trends Immunol 2001; 22: 633-640.
40. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141: 1231-1239, [1239, e1231-e1232].
41. Bozzano F, Picciotto A, Costa P, Marras F, Fazio V, Hirsch I, et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol 2011; 41: 2905-2914.
42. Yamagiwa S, Matsuda Y, Ichida T, Honda Y, Takamura M, Sugahara S, et al. Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res 2008; 38: 664-672.
43. Zhang S, Saha B, Kodys K, Szabo G. IFN-c production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol 2013; 59: 442-449.
44. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010; 138: 1536-1545.
45. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
46. Pelletier S, Drouin C, Bédard N, Khakoo SI, Bruneau J, Shoukry NH. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol 2010; 53: 805-816.
47. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
48. Morris SC, Orekhova T, Meadows MJ, Heidorn SM, Yang J, Finkelman FD. IL-4 induces in vivo production of IFN-gamma by NK and NKT cells. J Immunol 2006; 176: 5299-5305.
49. Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, et al. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clin Microbiol 1996; 34: 80-83.
50. Cavazza S, Lagging M. Indeterminate third-generation hepatitis C recombinant immunoblot assay and HCV RNA analysis: isolated reactivity against NS5 associated with HCV viraemia in clinical patients but not blood donors. Scand J Infect Dis 2005; 37: 488-492.
51. Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion 2004; 44: 349-358.
52. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J Neuroimmunol 1998; 83: 19-28.
53. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Crossreactivity between hepatitis C virus and Influenza A virus determinantspecific cytotoxic T cells. J Virol 2001; 75: 11392-11400.
54. Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, et al. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology 2006; 43: 602-611.
55. Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011; 54: 1135-1148.
56. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001; 107: 341-349.